-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 10th, the fifth batch of national procurement (hereinafter referred to as "this batch") began to declare information.
1
1Variety: the most in number, injections play the leading role
Variety: the most in number, injections play the leading roleThere are 60 varieties, 202 specifications, and 30 injections in this batch, which are the most since the previous national procurement.
There were only 3, 1, 3, and 8 injections in the first four batches, and the number of injections this time was nearly twice the sum of the previous four batches.
According to data from Minai.
2
2Treatment area: Digestion/metabolism and anti-infective drugs are still the mainstream
Treatment area: Digestion/metabolism and anti-infective drugs are still the mainstreamThis batch of varieties involved the most in the field of treatment are 12 digestion/metabolism, 11 anti-infection and 10 anti-tumor/immunomodulators.
3
3Competition level: slowing down
Competition level: slowing downUp to now, the number of companies that have passed the consistency evaluation of this batch of varieties are mostly concentrated in 2 (20 varieties), 3 (19 varieties) and 4 (10 varieties).
4
4Enterprises: China Biotech, Yangtze River, Qilu, and Kelun still have the most
Enterprises: China Biotech, Yangtze River, Qilu, and Kelun still have the mostThe largest number of varieties involved in this batch is China Biopharmaceuticals (13 varieties).
At the executive meeting of the State Council held on January 15th, the Premier requested that “centralized procurement should reduce the burden on patients while taking into account the reasonable profits of the enterprise” and “work hard to make this reform benefit patients, enterprises, and medical institutions.
The lowest bid price is no longer less than one dime.